Related Articles
Apatinib inhibits gastric carcinoma development by regulating the expression levels of IL‑17 via the Bax/Bcl‑2 signaling pathway
DUSP1 enhances the chemoresistance of gallbladder cancer via the modulation of the p38 pathway and DNA damage/repair system
Combined aspirin and apatinib treatment suppresses gastric cancer cell proliferation
Inhibition of miR‑101‑3p protects against sepsis‑induced myocardial injury by inhibiting MAPK and NF‑κB pathway activation via the upregulation of DUSP1
Apatinib sensitizes chemoresistant NSCLC cells to doxetaxel via regulating autophagy and enhances the therapeutic efficacy in advanced and refractory/recurrent NSCLC